Novo Nordisk is my top opportunity for 2026, driven by multiple catalysts and a compelling valuation. The Wegovy pill's FDA ...
Novo Nordisk has launched its first oral GLP-1 weight-loss pill in the United States, expanding beyond injectable treatments ...
The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...
The Canadian Press on MSN
Novo Nordisk considers competing with generics through renamed lower-price Ozempic
Health Canada is currently considering nine submissions from other drug companies to make generic semaglutide, the active ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
Daily Voice on MSN
Novo Nordisk's Wegovy pill released nationwide: What to know
The first oral glucagon-like peptide-1 (GLP-1) drug has launched nationwide, marking a major expansion of access to the ...
The drug is the first GLP-1 oral weight-loss drug for adults, though Eli Lilly expects approval for a version of Zepbound this year ...
Bidding to buy metabolic medicines biotech Metsera in September came down to two pharmaceutical giants, with Novo Nordisk’s higher offer losing out to Pfizer’s $4.9 billion price in part due to ...
Hosted on MSN
Why Novo Nordisk stock was melting on Monday
The Wegovy and Ozempic maker was hit with an analyst recommendation downgrade. A onetime bull now feels the stock is only a hold. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback